英国伦敦国王学院Pierre Guermonprez研究组取得一项新突破。他们对CD1c +人类树突状细胞（DC）的转录和功能进行分析，确定了原始CD8 + CD103 + T细胞的CD163 +亚群。该研究于2020年6月30日发表于《免疫学》。

他们确定了循环中的CD88-CD1c + CD163 + DC（称为DC3s）是炎性CD88-CD14 + CD1c + CD163 +FcεRI+ DC的直接前体。DC3通过GM-CSF激活的特定途径产生，独立于cDC限制（CDP）和单核细胞限制（cMoP）祖细胞。像经典的DC一样，但与单核细胞不同，DC3驱动了原始T细胞的激活。

在体外，DC3s具有通过转化生长因子β（TGF-β）信号转导表达组织归巢信号和上皮归巢α-E整合素（CD103）的CD8 + T细胞的独特能力。在体内，DC3s浸润腔内乳腺癌的原发性肿瘤，而DC3浸润与CD8 + CD103 + CD69 +组织驻留记忆T细胞正相关。总之，这些发现将DC3定义为具有明显调节肿瘤免疫力潜力的炎性DC谱系。

据悉，DC是控制T细胞活化的抗原呈递细胞。在人类中，DC亚群的多样性、个体发生学和功能能力尚不完全清楚。

附：英文原文

Title: Transcriptional and Functional Analysis of CD1c+ Human Dendritic Cells Identifies a CD163+ Subset Priming CD8+CD103+ T Cells

Author: Pierre Bourdely, Giorgio Anselmi, Kristine Vaivode, Rodrigo Nalio Ramos, Yoann Missolo-Koussou, Sofia Hidalgo, Jimena Tosselo, Nicolas Nuez, Wilfrid Richer, Anne Vincent-Salomon, Alka Saxena, Kristie Wood, Alvaro Lladser, Eliane Piaggio, Julie Helft, Pierre Guermonprez

Issue&Volume: 2020-06-30

Abstract: Dendritic cells (DCs) are antigen-presenting cells controlling T cell activation. In humans, the diversity, ontogeny, and functional capabilities of DC subsets are not fully understood. Here, we identified circulating CD88CD1c+CD163+ DCs (called DC3s) as immediate precursors of inflammatory CD88CD14+CD1c+CD163+FcεRI+ DCs. DC3s develop via a specific pathway activated by GM-CSF, independent of cDC-restricted (CDP) and monocyte-restricted (cMoP) progenitors. Like classical DCs but unlike monocytes, DC3s drove activation of naive T cells. In vitro, DC3s displayed a distinctive ability to prime CD8+ T cells expressing a tissue homing signature and the epithelial homing alpha-E integrin (CD103) through transforming growth factor β (TGF-β) signaling. In vivo, DC3s infiltrated luminal breast cancer primary tumors, and DC3 infiltration correlated positively with CD8+CD103+CD69+ tissue-resident memory T cells. Together, these findings define DC3s as a lineage of inflammatory DCs endowed with a strong potential to regulate tumor immunity.

DOI: 10.1016/j.immuni.2020.06.002

Source: https://www.cell.com/immunity/fulltext/S1074-7613(20)30232-6